Literature DB >> 35838799

The impact of bicuspid aortic valve morphology on von Willebrand factor function in patients with severe aortic stenosis and its change after TAVI.

Carsten Jungbauer1, Kurt Debl1, Nastasia Roth2, Carolin Heidel1, Congde Xu1, Ute Hubauer1, Stefan Wallner3, Christine Meindl1, Andreas Holzamer4, Michael Hilker4, Marcus Creutzenberg5, Samuel Sossalla1, Lars Maier1.   

Abstract

BACKGROUND: Aortic stenosis (AS) can cause acquired von Willebrand syndrome (AVWS) and valve replacement has been shown to lead to von Willebrand factor (vWF) recovery. The aim of the current study was to investigate the prevalence of AVWS in different severe AS phenotypes and its course after transcatheter aortic valve implantation (TAVI).
METHODS: 143 patients with severe AS undergoing TAVI were included in the study. vWF function was assessed at baseline, 6 and 24 h after TAVI. AVWS was defined as a reduced vWF:Ac/Ag ratio ≤ 0.7. Phenotypes were classified by tricuspid (TAV) and bicuspid (BAV) valve morphology, mean transvalvular gradient (Pmean), stroke volume index (SVI), ejection fraction (EF) and indexed effective orifice area (iEOA).
RESULTS: AVWS was present in 36 (25.2%) patients before TAVI. vWF:Ac/Ag ratio was significantly lower in high gradient compared to low-gradient severe AS [0.78 (IQR 0.67-0.86) vs. 0.83 (IQR 0.74-0.93), p < 0.05] and in patients with BAV compared to TAV [0.70 (IQR 0.63-0.78) vs. 0.81 (IQR 0.71-0.89), p < 0.05]. Normalization of vWF:Ac/Ag ratio was achieved in 61% patients 24 h after TAVI. As in the overall study cohort, vWF:Ac/Ag ratio increased significantly in all severe AS subgroups 6 h after TAVI (each p < 0.05). Regarding binary logistic regression analysis, BAV was the only significant predictor for AVWS.
CONCLUSIONS: BAV morphology is a strong predictor for AVWS in severe AS. TAVI restores vWF function in most patients with severe AS independently of AS phenotype and valve morphology.
© 2022. The Author(s).

Entities:  

Keywords:  Acquired von Willebrand syndrome; Aortic stenosis; Bicuspid aortic valve; Transcatheter aortic valve implantation; von Willebrand factor

Year:  2022        PMID: 35838799     DOI: 10.1007/s00392-022-02047-6

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   6.138


  25 in total

1.  Effects of transcutaneous aortic valve implantation on aortic valve disease-related hemostatic disorders involving von Willebrand factor.

Authors:  Thibault Caspar; Laurence Jesel; Dominique Desprez; Lélia Grunebaum; Hafida Samet; Annie Trinh; Hélène Petit-Eisenmann; Michel Kindo; Patrick Ohlmann; Olivier Morel
Journal:  Can J Cardiol       Date:  2015-01-24       Impact factor: 5.223

2.  From clinical observation to mechanism--Heyde's syndrome.

Authors:  Joseph Loscalzo
Journal:  N Engl J Med       Date:  2012-11-15       Impact factor: 91.245

Review 3.  Von Willebrand's Disease.

Authors:  Frank W G Leebeek; Jeroen C J Eikenboom
Journal:  N Engl J Med       Date:  2016-11-24       Impact factor: 91.245

4.  2017 ESC/EACTS Guidelines for the management of valvular heart disease.

Authors:  Helmut Baumgartner; Volkmar Falk; Jeroen J Bax; Michele De Bonis; Christian Hamm; Per Johan Holm; Bernard Iung; Patrizio Lancellotti; Emmanuel Lansac; Daniel Rodriguez Muñoz; Raphael Rosenhek; Johan Sjögren; Pilar Tornos Mas; Alec Vahanian; Thomas Walther; Olaf Wendler; Stephan Windecker; Jose Luis Zamorano
Journal:  Eur Heart J       Date:  2017-09-21       Impact factor: 29.983

Review 5.  von Willebrand Factor and Management of Heart Valve Disease: JACC Review Topic of the Week.

Authors:  Eric Van Belle; Flavien Vincent; Antoine Rauch; Caterina Casari; Emmanuelle Jeanpierre; Valentin Loobuyck; Mickael Rosa; Cedric Delhaye; Hughes Spillemaeker; Camille Paris; Nicolas Debry; Basile Verdier; André Vincentelli; Annabelle Dupont; Peter J Lenting; Sophie Susen
Journal:  J Am Coll Cardiol       Date:  2019-03-12       Impact factor: 24.094

6.  Treatment of acquired von Willebrand syndrome in aortic stenosis with transcatheter aortic valve replacement.

Authors:  Tobias Spangenberg; Ulrich Budde; Dimitry Schewel; Christian Frerker; Thomas Thielsen; Karl-Heinz Kuck; Ulrich Schäfer
Journal:  JACC Cardiovasc Interv       Date:  2015-04-27       Impact factor: 11.195

7.  Von Willebrand Factor Multimers during Transcatheter Aortic-Valve Replacement.

Authors:  Eric Van Belle; Antoine Rauch; Flavien Vincent; Emmanuel Robin; Marion Kibler; Julien Labreuche; Emmanuelle Jeanpierre; Marie Levade; Christopher Hurt; Natacha Rousse; Jean-Baptiste Dally; Nicolas Debry; Jean Dallongeville; Andre Vincentelli; Cedric Delhaye; Jean-Luc Auffray; Francis Juthier; Guillaume Schurtz; Gilles Lemesle; Thibault Caspar; Olivier Morel; Nicolas Dumonteil; Alain Duhamel; Camille Paris; Annabelle Dupont-Prado; Paulette Legendre; Frederic Mouquet; Berenice Marchant; Sylvie Hermoire; Delphine Corseaux; Karim Moussa; Aurelie Manchuelle; Jean-Jacques Bauchart; Valentin Loobuyck; Claudine Caron; Christophe Zawadzki; Fabrice Leroy; Jean-Christophe Bodart; Bart Staels; Jenny Goudemand; Peter J Lenting; Sophie Susen
Journal:  N Engl J Med       Date:  2016-07-28       Impact factor: 91.245

8.  Acquired von Willebrand syndrome in aortic stenosis.

Authors:  André Vincentelli; Sophie Susen; Thierry Le Tourneau; Isabelle Six; Olivier Fabre; Francis Juthier; Anne Bauters; Christophe Decoene; Jenny Goudemand; Alain Prat; Brigitte Jude
Journal:  N Engl J Med       Date:  2003-07-24       Impact factor: 91.245

Review 9.  Acquired von Willebrand Syndrome Associated with Cardiovascular Diseases.

Authors:  Hisanori Horiuchi; Tsuyoshi Doman; Koichi Kokame; Yoshikatsu Saiki; Masanori Matsumoto
Journal:  J Atheroscler Thromb       Date:  2019-03-12       Impact factor: 4.928

10.  Pre-procedural abnormal function of von Willebrand Factor is predictive of bleeding after surgical but not transcatheter aortic valve replacement.

Authors:  Kajetan Grodecki; Karol Zbroński; Elżbieta Przybyszewska-Kazulak; Anna Olasińska-Wiśniewska; Radosław Wilimski; Bartosz Rymuza; Piotr Scisło; Paweł Czub; Dominika Koper; Janusz Kochman; Katarzyna Pawlak; Olga Ciepiela; Marek Grygier; Marek Jemielity; Maciej Lesiak; Krzysztof J Filipiak; Grzegorz Opolski; Zenon Huczek
Journal:  J Thromb Thrombolysis       Date:  2019-11       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.